Company Description
Evotec SE operates as a drug discovery and development company in the United States, Germany, France, the United Kingdom, Switzerland, and internationally.
It operates in two segments, Shared R&D and Just – Evotec Biologics. The company is developing pharmaceutical products in various therapeutic areas, such as oncology, autoimmune, cancer, diabetes, heart failure, immunology, pain and inflammation, infectious, kidney, liver, respiratory, fibrotic and metabolic disease, and rare diseases; central nervous system (CNS) and cardiometabolic diseases; and animal and women health.
The company has collaboration agreements with Mass General Brigham and Joslin Diabetes Center focusing on cardiometabolic diseases; BMS antiviral; Novo Nordisk cell therapy; University of Oxford; German Cancer Research Center; University Hospital in Hamburg; University of Toronto, Harvard, and Yale; Johns Hopkins University; Ospedale San Raffaele (OSR); and National University of Singapore.
It has a partnership with LAB282, LAB150, beLAB2122, beLAB1407, LAB eN², Danube Labs, VC Amplitude Ventures, LaB eN2, and 65LAB.
The company serves pharma and biotechnology companies, academic institutions, patient advocacy groups, and venture capital.
The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.
| Country | Germany |
| Founded | 1993 |
| IPO Date | Nov 4, 2021 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 4,740 |
| CEO | Christian Wojczewski |
Contact Details
Address: Essener Bogen 7 Hamburg, 22419 Germany | |
| Phone | 49 40 560 81 0 |
| Website | evotec.com |
Stock Details
| Ticker Symbol | EVO |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | EUR |
| IPO Price | $26.16 |
| CIK Code | 1412558 |
| CUSIP Number | 30050E105 |
| ISIN Number | US30050E1055 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Christian Wojczewski Ph.D. | Chief Executive Officer and Management Board Member |
| Dr. Cord Dohrmann Ph.D. | Chief Scientific Officer and Member of Management Board |
| Aurelie Dalbiez | Chief People Officer and Member of Management Board |
| Paul Hitchin | Chief Financial Officer and Member of Management Board |
| Dr. Sarah Fakih | Executive Vice President, Head of Global Communications and Investor Relations |
| Dr. Christian Dargel | Executive Vice President Global Head of Legal and Compliance |
| Dr. Ian M. Hunneyball | Senior Vice President of Programme Management and Clinical Operations |
| Dr. David Hallet | Executive Vice President |
| Uwe Andag | Executive Vice President Head of Metabolic Diseases |
| Christiane Honisch | SVice President Head of Diagnostics |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jan 16, 2026 | 6-K | Report of foreign issuer |
| Jan 16, 2026 | SCHEDULE 13G | Filing |
| Jan 13, 2026 | 6-K | Report of foreign issuer |
| Jan 8, 2026 | 6-K | Report of foreign issuer |
| Jan 6, 2026 | 6-K | Report of foreign issuer |
| Jan 2, 2026 | 6-K | Report of foreign issuer |
| Jan 2, 2026 | 6-K | Report of foreign issuer |
| Dec 8, 2025 | 6-K | Report of foreign issuer |
| Nov 14, 2025 | SCHEDULE 13G/A | Filing |
| Nov 6, 2025 | 6-K | Report of foreign issuer |